MX2023015121A - Metodos de uso de inhibidores de aldosterona sintasa. - Google Patents
Metodos de uso de inhibidores de aldosterona sintasa.Info
- Publication number
- MX2023015121A MX2023015121A MX2023015121A MX2023015121A MX2023015121A MX 2023015121 A MX2023015121 A MX 2023015121A MX 2023015121 A MX2023015121 A MX 2023015121A MX 2023015121 A MX2023015121 A MX 2023015121A MX 2023015121 A MX2023015121 A MX 2023015121A
- Authority
- MX
- Mexico
- Prior art keywords
- aldosterone synthase
- methods
- synthase inhibitors
- subject
- compound
- Prior art date
Links
- 229940123338 Aldosterone synthase inhibitor Drugs 0.000 title 1
- 229940125904 compound 1 Drugs 0.000 abstract 2
- 208000016998 Conn syndrome Diseases 0.000 abstract 1
- 101000761956 Homo sapiens Cytochrome P450 11B2, mitochondrial Proteins 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000013846 primary aldosteronism Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163214521P | 2021-06-24 | 2021-06-24 | |
| US202163290364P | 2021-12-16 | 2021-12-16 | |
| PCT/US2022/073148 WO2022272300A1 (en) | 2021-06-24 | 2022-06-24 | Methods of using aldosterone synthase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023015121A true MX2023015121A (es) | 2024-04-16 |
Family
ID=84545863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023015121A MX2023015121A (es) | 2021-06-24 | 2022-06-24 | Metodos de uso de inhibidores de aldosterona sintasa. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240277698A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4358959A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024523559A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240035483A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2022299103B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023027025A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3223211A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL309428A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023015121A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022272300A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026521801A (ja) * | 2023-06-29 | 2026-07-01 | アストラゼネカ アイルランド リミテッド | バクスドロスタットの結晶形、並びにその製造方法及びその使用 |
| CN121712504A (zh) * | 2023-07-27 | 2026-03-20 | 矿物疗法公司 | 用洛伦司他及两种或更多种降压药的组合治疗高血压的方法 |
| IL329013A (en) * | 2023-12-15 | 2026-08-01 | Astrazeneca Ireland Ltd | SGLT2 inhibitors and baxadrostat for the treatment of chronic kidney disease and hypertension |
| WO2026120166A1 (en) | 2024-12-06 | 2026-06-11 | AstraZeneca Ireland Limited | Tablet formulation |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996024358A1 (en) * | 1995-02-10 | 1996-08-15 | G.D. Searle & Co. | Use of low dose amount of spironolactone for treatment of cardiovascular disease |
| AU4866196A (en) * | 1995-02-10 | 1996-08-27 | G.D. Searle & Co. | Combination of angiotensin converting enzyme inhibitor, side-effect-reduced amount of aldosterone antagonist and diuretic |
| US20070196510A1 (en) * | 2006-02-17 | 2007-08-23 | Gerber Michael J | Method for treating resistant hypertension |
| CA2832996C (en) * | 2011-04-26 | 2019-05-07 | Merck Sharp & Dohme Corp. | Tricyclic triazole compounds and their use as aldosterone synthase inhibitors |
| US9353081B2 (en) * | 2011-09-23 | 2016-05-31 | Hoffmann-La Roche Inc. | Bicyclic dihydroquinoline-2-one derivatives |
-
2022
- 2022-06-24 JP JP2023579554A patent/JP2024523559A/ja active Pending
- 2022-06-24 WO PCT/US2022/073148 patent/WO2022272300A1/en not_active Ceased
- 2022-06-24 EP EP22829524.2A patent/EP4358959A4/en active Pending
- 2022-06-24 KR KR1020247002601A patent/KR20240035483A/ko active Pending
- 2022-06-24 US US18/569,853 patent/US20240277698A1/en active Pending
- 2022-06-24 BR BR112023027025A patent/BR112023027025A2/pt unknown
- 2022-06-24 AU AU2022299103A patent/AU2022299103B2/en active Active
- 2022-06-24 MX MX2023015121A patent/MX2023015121A/es unknown
- 2022-06-24 CA CA3223211A patent/CA3223211A1/en active Pending
- 2022-06-24 IL IL309428A patent/IL309428A/en unknown
-
2026
- 2026-03-16 AU AU2026201954A patent/AU2026201954A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4358959A1 (en) | 2024-05-01 |
| CA3223211A1 (en) | 2022-12-29 |
| WO2022272300A1 (en) | 2022-12-29 |
| IL309428A (en) | 2024-02-01 |
| KR20240035483A (ko) | 2024-03-15 |
| US20240277698A1 (en) | 2024-08-22 |
| JP2024523559A (ja) | 2024-06-28 |
| AU2026201954A1 (en) | 2026-04-02 |
| AU2022299103A1 (en) | 2024-01-25 |
| EP4358959A4 (en) | 2025-05-14 |
| BR112023027025A2 (pt) | 2024-03-12 |
| AU2022299103B2 (en) | 2025-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022007527A (es) | Inhibidores de proteinas kras mutantes. | |
| MX2024008551A (es) | Terapias de combinacion. | |
| MX2021009562A (es) | Combinacion farmaceutica que comprende tno155 y un inhibidor de pd-1. | |
| BR112022022634A2 (pt) | Inibidores de atr para o tratamento de câncer | |
| MX2021002804A (es) | Terapias de combinacion. | |
| SV2011003853A (es) | Compuestos organicos | |
| EA201291309A1 (ru) | ПРИМЕНЕНИЕ sGC СТИМУЛЯТОРОВ, sGC АКТИВАТОРОВ, ОДНИХ И В КОМБИНАЦИИ С PDE5 ИНГИБИТОРАМИ, ДЛЯ ЛЕЧЕНИЯ СИСТЕМНОГО СКЛЕРОЗА (SSc) | |
| AR119934A1 (es) | Inhibidores de pikfyve para terapia contra el cáncer | |
| MX2024004216A (es) | Terapias combinadas de inhibidores de kras g12d con inhibidores de la familia pan erbb. | |
| BR112023027025A2 (pt) | Métodos de uso de inibidores da aldosterona sintase | |
| AR075501A1 (es) | Uso de inhibidores de la succinato deshidrogenasa para combatir infecciones primarias por oidio | |
| NI201100048A (es) | Aminotriazolopiridinas y su uso como inhibidores de la cinasa. | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| BR112014028041A2 (pt) | tratamento de obesidade hipotalâmica com inibidores de metap2 | |
| MX2022001004A (es) | Inhibidores de enzimas. | |
| EA202190776A1 (ru) | Комбинация маломолекулярных ингибиторов cd-47 с другими противораковыми агентами | |
| CO2022000270A2 (es) | Inhibidores de enzimas | |
| CO2025005378A2 (es) | Compuestos n-(5-sustituido-[(1,3,4-tiadiazolil) o (1,3-tiazolil)](sustituido)carboxamida, composiciones farmacéuticas y métodos de preparación de los compuestos amida y de su uso | |
| CL2022001353A1 (es) | Inhibidores de egfr | |
| MX387658B (es) | Métodos para tratar y/o prevenir queratosis actínica. | |
| CO2022000266A2 (es) | Inhibidores de enzimas | |
| AR074214A1 (es) | Inhibidores de la fosfodiesterasa tipo iii (pde iii) o agentes sensiblizantes al ca2+ para el tratamiento de la cardiomiopatia hipertrofica | |
| CL2022003400A1 (es) | Uso del inhibidor de la fosfodiesterasa a 10 para el tratamiento del síndrome de tourette | |
| BR112022022305A2 (pt) | Combinação farmacêutica que compreende tno155 e nazartinibe | |
| CL2010001618A1 (es) | Compuestos derivados de oxazolidinona sustituida con un grupo amidoxima ciclica o amidrazona ciclica, inhibidores del factor xa; composicion farmaceutica; y su uso para prevenir o tratar trombosis, infarto al miocardio, arteriosclerosis, entre otras enfermedades. |